PMID- 25732842
OWN - NLM
STAT- MEDLINE
DCOM- 20151215
LR  - 20220330
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 21
IP  - 5
DP  - 2015 Apr
TI  - Glial and neuronal markers in cerebrospinal fluid predict progression in multiple 
      sclerosis.
PG  - 550-61
LID - 10.1177/1352458514549397 [doi]
AB  - OBJECTIVE: To investigate glial and neuronal biomarkers in cerebrospinal fluid 
      (CSF) samples from patients with relapsing-remitting multiple sclerosis (RRMS) 
      and clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS), and 
      to evaluate their ability to predict conversion from CIS to clinically definite 
      MS (CDMS) and also disability progression in MS. METHODS: CSF levels of 
      neurofilament light protein (NFL), t-tau, p-tau, glial fibrillary acidic protein 
      (GFAP), S-100B, human chitinase 3-like 1 protein (YKL-40), monocyte 
      chemoattractant protein-1 (MCP-1), alpha-sAPP and beta-sAPP; and Abeta38, Abeta40 and Abeta42, 
      were analyzed in 109 CIS patients and 192 RRMS patients. The mean follow-up time 
      of these 301 patients was 11.7 +/- 6.4 years. RESULTS: High levels of NFL were 
      associated with early conversion from CIS to CDMS (hazard ratio (HR) with 95% 
      confidence interval (CI): 2.69 (1.75 - 4.15); p < 0.0001). High levels of YKL-40 
      and GFAP were associated with earlier progression in the Expanded Disability 
      Status Scale (EDSS), score 3: YKL-40 (HR (95% CI): 2.78 (1.48 - 5.23); p = 0.001) 
      and GFAP (HR (95% CI): 1.83 (1.01 - 3.35); p = 0.04). High levels of YKL-40 were 
      associated with earlier progression to EDSS 6 (HR (95% CI): 4.57 (1.01 - 20.83); 
      p = 0.05). CONCLUSIONS: CSF levels of NFL in CIS patients are an independent 
      prognostic marker for conversion to CDMS. Whereas, CSF levels of YKL-40 and GFAP 
      are independent prognostic markers for disability progression in MS.
CI  - (c) The Author(s), 2015.
FAU - Martinez, M Alba Mane
AU  - Martinez MA
AD  - Joan XXIII University Hospital, Universitat Rovira i Virgili, Tarragona, 
      Spain/Bellvitge University Hospital, Universitat de Barcelona, L'Hospitalet de 
      Llobregat, Barcelona, Spain amane.hj23.ics@gencat.cat.
FAU - Olsson, Bob
AU  - Olsson B
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of 
      Gothenburg, Molndal, Sweden.
FAU - Bau, Laura
AU  - Bau L
AD  - Bellvitge University Hospital, Universitat de Barcelona, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Matas, Elisabet
AU  - Matas E
AD  - Bellvitge University Hospital, Universitat de Barcelona, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Cobo Calvo, Alvaro
AU  - Cobo Calvo A
AD  - Bellvitge University Hospital, Universitat de Barcelona, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Andreasson, Ulf
AU  - Andreasson U
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of 
      Gothenburg, Molndal, Sweden.
FAU - Blennow, Kaj
AU  - Blennow K
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of 
      Gothenburg, Molndal, Sweden.
FAU - Romero-Pinel, Lucia
AU  - Romero-Pinel L
AD  - Bellvitge University Hospital, Universitat de Barcelona, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Martinez-Yelamos, Sergio
AU  - Martinez-Yelamos S
AD  - Bellvitge University Hospital, Universitat de Barcelona, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Zetterberg, Henrik
AU  - Zetterberg H
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of 
      Gothenburg, Molndal, Sweden/Institute of Neurology, University College London, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20150302
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Biomarkers/*cerebrospinal fluid
MH  - Disability Evaluation
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Multiple Sclerosis/*cerebrospinal fluid/diagnosis
MH  - Multiple Sclerosis, Relapsing-Remitting/cerebrospinal fluid/diagnosis
MH  - Neuroglia/*metabolism
MH  - Neurons/*metabolism
MH  - Prognosis
MH  - Recurrence
PMC - PMC4390605
OTO - NOTNLM
OT  - Biomarkers
OT  - cerebrospinal fluid
OT  - chitinase 3-like 1 protein
OT  - diagnostics
OT  - disability progression
OT  - glial fibrillary acidic protein
OT  - multiple sclerosis
OT  - neurofilament light protein
OT  - prognostic markers
COIS- Conflict of interest: M Alba Mane Martinez received research support from the 
      Fundacio Hospital Universitari de Tarragona Joan XXIII and Fundacio Institut 
      d'Investigacio Biomedica de Bellvitge (IDIBELL); and received research support, 
      funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical 
      Industries, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering Pharma. 
      Laura Bau received research support, funding for travel and congress expenses 
      from Biogen Idec, Teva, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering 
      pharmaceuticals. Elisabet Matas received research support, funding for travel and 
      congress expenses from Biogen Idec, Teva, Sanofi-Aventis, Merck Serono, Novartis 
      and Bayer Schering pharmaceuticals. Alvaro Cobo Calvo received research support, 
      funding for travel and congress expenses from Biogen Idec, Teva, Sanofi-Aventis, 
      Merck Serono, Novartis and Bayer Schering pharmaceuticals. Kaj Blennow has served 
      on the advisory board for Innogenetics of Belgium. Lucia Romero-Pinel received 
      research support, funding for travel and congress expenses from Biogen Idec, 
      Teva, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering pharmaceuticals. 
      Sergio Martinez-Yelamos received honoraria compensation to participate in 
      advisory boards, collaborations as a consultant and scientific communications 
      from Biogen Idec, Teva, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering 
      pharmaceuticals; and received research support, funding for travel and congress 
      expenses from Biogen Idec, Teva, Sanofi-Aventis, Merck Serono, Novartis and Bayer 
      Schering pharmaceuticals. Ulf Andreasson, Bob Olsson and Henrik Zetterberg report 
      no disclosures.
EDAT- 2015/03/04 06:00
MHDA- 2015/12/17 06:00
PMCR- 2015/04/09
CRDT- 2015/03/04 06:00
PHST- 2015/03/04 06:00 [entrez]
PHST- 2015/03/04 06:00 [pubmed]
PHST- 2015/12/17 06:00 [medline]
PHST- 2015/04/09 00:00 [pmc-release]
AID - 1352458514549397 [pii]
AID - 10.1177_1352458514549397 [pii]
AID - 10.1177/1352458514549397 [doi]
PST - ppublish
SO  - Mult Scler. 2015 Apr;21(5):550-61. doi: 10.1177/1352458514549397. Epub 2015 Mar 
      2.